News stories about Cytori Therapeutics (NASDAQ:CYTX) have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytori Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.2769983043289 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Cytori Therapeutics (NASDAQ CYTX) opened at 0.3661 on Tuesday. Cytori Therapeutics has a 52 week low of $0.31 and a 52 week high of $2.29. The company’s market capitalization is $11.89 million. The company has a 50-day moving average of $0.78 and a 200-day moving average of $1.19.

Cytori Therapeutics (NASDAQ:CYTX) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.23 million. Cytori Therapeutics had a negative return on equity of 205.28% and a negative net margin of 450.34%. The business’s revenue was down 18.2% on a year-over-year basis. During the same period last year, the company posted ($0.43) EPS. On average, equities research analysts anticipate that Cytori Therapeutics will post ($0.60) EPS for the current year.

A number of research analysts recently issued reports on CYTX shares. B. Riley reissued a “buy” rating and issued a $2.30 price objective on shares of Cytori Therapeutics in a research note on Wednesday, May 10th. Zacks Investment Research raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research note on Tuesday, July 11th. Maxim Group set a $10.00 price objective on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Wednesday, May 31st. Finally, ValuEngine cut shares of Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st.

WARNING: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/cytori-therapeutics-cytx-getting-somewhat-favorable-press-coverage-accern-reports/1490879.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Insider Buying and Selling by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.